about
Norwalk virus shedding after experimental human infectionComprehensive analysis of a norovirus-associated gastroenteritis outbreak, from the environment to the consumerStructural basis of glycan interaction in gastroenteric viral pathogensStructural Analysis of Histo-Blood Group Antigen Binding Specificity in a Norovirus GII.4 Epidemic Variant: Implications for Epochal EvolutionStructural Analysis of Determinants of Histo-Blood Group Antigen Binding Specificity in Genogroup I NorovirusesSeroepidemiology of norovirus-associated travelers' diarrheaNoroviruses as a cause of diarrhea in travelers to Guatemala, India, and MexicoEffect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial.Antiviral targets of human norovirusesSafety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations.Preparing for a possible pandemic: influenza A/H5N1 vaccine development.Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009-2010 seasonal trivalent influenza vaccinationsAdjuvants for pandemic influenza vaccines.Vaccines for pandemic influenza: summary of recent clinical trials.Human Sera Collected between 1979 and 2010 Possess Blocking-Antibody Titers to Pandemic GII.4 Noroviruses Isolated over Three Decades.Evaluation of age-related differences in the immunogenicity of a G9 H9N2 influenza vaccinePrior infections with seasonal influenza A/H1N1 virus reduced the illness severity and epidemic intensity of pandemic H1N1 influenza in healthy adults.Evaluations for in vitro correlates of immunogenicity of inactivated influenza a H5, H7 and H9 vaccines in humans.Antibody correlates and predictors of immunity to naturally occurring influenza in humans and the importance of antibody to the neuraminidase.Rapid research response to the 2009 A(H1N1)pdm09 influenza pandemic (Revised).Recovery of drug-resistant influenza virus from immunocompromised patients: a case series.Increased fluoroquinolone resistance with time in Escherichia coli from >17,000 patients at a large county hospital as a function of culture site, age, sex, and location.B-Cell Responses to Intramuscular Administration of a Bivalent Virus-Like Particle Human Norovirus Vaccine.A high dosage influenza vaccine induced significantly more neuraminidase antibody than standard vaccine among elderly subjects.Replication and packaging of Norwalk virus RNA in cultured mammalian cells.A phase I evaluation of inactivated influenza A/H5N1 vaccine administered by the intradermal or the intramuscular route.Noroviruses - State of the Art.Norwalk virus does not replicate in human macrophages or dendritic cells derived from the peripheral blood of susceptible humans.Serological correlate of protection against norovirus-induced gastroenteritisInactivated influenza vaccination for people with spinal cord injuryImmunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus.Development of a Gaussia luciferase-based human norovirus protease reporter system: cell type-specific profile of Norwalk virus protease precursors and evaluation of inhibitors.Plasmid-based human norovirus reverse genetics system produces reporter-tagged progeny virus containing infectious genomic RNA.Identification of human single-chain antibodies with broad reactivity for noroviruses.Epidemiology of human noroviruses and updates on vaccine developmentRespiratory viral infections in patients with chronic, obstructive pulmonary disease.Norwalk virus-like particle hemagglutination by binding to h histo-blood group antigensNorwalk virus infection and disease is associated with ABO histo-blood group type.Replication of human noroviruses in stem cell-derived human enteroids.Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy.
P50
Q22305638-808FC3F1-8C28-4320-8A1A-3F25BFB450DFQ24633483-2F4F0695-6D36-4FC6-AA32-54D66AC97711Q27030776-BC44958B-5E45-4DB9-9BC5-EE6123CD3F14Q27670610-A067F823-E1C9-4926-B8D9-D20093312478Q27682308-A0DAD978-8E26-4DFF-AA08-280F5D1ADA47Q28395024-7F7EB309-EAE0-472F-8FBB-D815B72E1D80Q28395207-563225BA-419A-4AD6-9AE4-1DD639878A1CQ30203099-9E71C33E-F07F-4C7E-BB1B-8BF8D27EED1CQ30249527-2AD641EA-12C4-4571-9A87-D16B29783EA4Q30357294-6FB00B31-1266-48C9-BB08-E8F78EA8A9B7Q30362968-78E48F08-1F3A-4A69-8897-6A9FB512907DQ30369098-AE7201CF-D073-4AB8-B33E-681E3585698BQ30380906-0947850A-A05B-4826-822E-FF3D2ABDFDEDQ30380913-0831A727-A2B8-4BFA-B557-43556D818A19Q30401642-F8CB2369-6C2F-4B51-94B9-30DE5B7AFF5AQ30406344-998D7C05-FB30-4106-B8EB-F13CA3130F22Q30409342-E9249857-394D-422F-ABEF-8BFC1A358444Q30424758-A52EE9D8-CBB4-4674-9A80-05495D4EEB74Q30425783-F6DC56A7-1566-41A1-83E8-C332ED49C230Q30430120-C2F76986-0515-4DEE-A7DD-73B58CB8CCAAQ30439558-962B4737-E722-4D97-9EF5-96857C6F4AC2Q33314977-39103F7A-9F07-4B86-8782-CEB1C8E8EF9DQ33654573-6B4E0F28-D131-41E5-BFBE-38120D1A8B4CQ33782762-64E583B4-59D4-4480-8128-38F46BEDE8D7Q33900425-4A9F5967-ACCB-4DE0-BDFB-2120AC685936Q34034402-19FE902D-2AD2-424A-98E6-D9FAFA31D042Q34090629-C7D6F3E0-1DB9-415E-8147-A8563639070EQ34105555-E8F7B3C9-E016-4433-8A21-10938FDD7680Q34153875-674A0F30-CC54-4D7E-A147-F301B29106ADQ34200962-D786359B-CB88-4935-9F96-B7A1D93B4552Q34247261-CAA12D45-6A1B-45E6-BDF0-C0CBDA6C0B11Q34262075-D4238E9B-9594-4C97-9B7C-54343DE53917Q34281184-AC4D8CF4-2BD0-456B-BC52-39737EFD9EEFQ34313167-7F9B6E79-CB27-4F4C-9172-C9D848325A85Q34385139-3A7D0212-DB5B-4ABA-8FBD-D13E548DA94FQ34413068-4981734C-11DA-4C8C-B58B-A15A113252EDQ34461894-3DFEDC6F-6EEE-4C2F-8BEE-C1BADF3C05FBQ34523042-2494F8D0-C8A4-4981-969D-333C4133AB5DQ34538562-BE1C09D6-C2BD-4278-A119-ED66FBDC99B7Q34629205-E1F33E94-D76D-46BD-A8DC-DF8FE6C23F8D
P50
name
Robert L Atmar
@ast
Robert L Atmar
@en
Robert L Atmar
@es
Robert L Atmar
@nl
type
label
Robert L Atmar
@ast
Robert L Atmar
@en
Robert L Atmar
@es
Robert L Atmar
@nl
prefLabel
Robert L Atmar
@ast
Robert L Atmar
@en
Robert L Atmar
@es
Robert L Atmar
@nl